Kazia Doses First Patient in Pediatric Brain Cancer Study
Image
Sydney – September 13, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.
Preclinical data showed the combination nearly quadrupled median survival in an AT/RT model
In an orthotopic AT/RT preclinical model, the paxalisib-gemcitabine combination extended median survival from 22 to 82.5 days (p0.0001) and showed complementary anti-tumor activity across multiple AT/RT cell lines. These findings, previously presented at ISPNO, AACR and Neuro-Oncology meetings, formed the scientific basis for advancing into the multicenter PNOC035 trial.